Teva to Host Conference Call to Discuss Second Quarter 2023 Financial Results at 8 a.m. ET on August 2, 2023 Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today…
Women and girls bear brunt of water and sanitation crisis – new UNICEF-WHO report Globally, women are most likely to be responsible for fetching water for households, while girls are…
Syneos Health Strengthens Asia Pacific Leadership Syneos Health® (Nasdaq: SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced Shigeto Miyamoto as Vice President of Digital Solutions for Asia Pacific. In…
WHO Regional Adviser for Prevention and response to sexual misconduct in South-East Asia Anju Pandey is a feminist, humanist and gender trainer. She joined WHO’s Regional Office for South-East Asia…
The new approach in cancer therapy with innovative mechanism-of-action for ferroptosis induction A team of researchers led by Dr. Marcus Conrad from Helmholtz Munich discovered a novel anti-cancer drug, called…
FDA Approves Pfizer’s NGENLA™, a Long-Acting Once-Weekly Treatment for Pediatric Growth Hormone Deficiency NEW YORK & MIAMI–(BUSINESS WIRE)– Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced today…
AstraZeneca announces $400 million investment in reforestation and biodiversity in support of climate action and human health AstraZeneca has announced a $400 million investment in its global AZ Forest programme,…
AbbVie and Genmab Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL) AbbVie (NYSE: ABBV) and Genmab (Nasdaq: GMAB)…
FDA approves Pfizer’s LITFULO™ (ritlecitinib) for adults and adolescents with severe alopecia areata Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has approved LITFULO™ (ritlecitinib),…
Magdeburg researchers discover a new mechanism of cancer immune defense Modern immunotherapies boost the body’s own defenses against cancer. They activate killer T cells of the immune system that can…
Kite Announces Completion of Marketing Authorization Transfer for Yescarta® CAR T-cell Therapy in Japan SANTA MONICA, Calif.–(BUSINESS WIRE)– Kite Pharma, Inc., a Gilead Company (Nasdaq: GILD), today announced that the Marketing…
Ad hoc announcement pursuant to Art. 53 LRFerring Pharmaceuticals appoints new Executive Chairman among key changes to Board of Directors Ferring Pharmaceuticals announced today that Jean-Frédéric Paulsen has been appointed…